431 related articles for article (PubMed ID: 23846012)
1. Aliskiren improves blood pressure control and prevents cardiac damage in high-risk hypertensive subjects.
Mazza A; Montemurro D; Zuin M; Schiavon L; Zorzan S; Chondrogiannis S; Ferretti A; Ramazzina E; Rubello D
Minerva Cardioangiol; 2013 Aug; 61(4):461-9. PubMed ID: 23846012
[TBL] [Abstract][Full Text] [Related]
2. Aliskiren improves blood pressure control and prevents cardiac damage in high-risk hypertensive subjects.
Mazza A; Montemurro D; Zuin M; Schiavon L; Zorzan S; Chondrogiannis S; Ferretti A; Ramazzina E; Rubello D
Minerva Cardioangiol; 2013 Feb; ():. PubMed ID: 23370164
[TBL] [Abstract][Full Text] [Related]
3. Effects of the direct renin inhibitor aliskiren and atenolol alone or in combination in patients with hypertension.
Dietz R; Dechend R; Yu CM; Bheda M; Ford J; Prescott MF; Keefe DL
J Renin Angiotensin Aldosterone Syst; 2008 Sep; 9(3):163-75. PubMed ID: 18957387
[TBL] [Abstract][Full Text] [Related]
4. Efficacy and safety of the direct renin inhibitor aliskiren and ramipril alone or in combination in patients with diabetes and hypertension.
Uresin Y; Taylor AA; Kilo C; Tschöpe D; Santonastaso M; Ibram G; Fang H; Satlin A
J Renin Angiotensin Aldosterone Syst; 2007 Dec; 8(4):190-8. PubMed ID: 18205098
[TBL] [Abstract][Full Text] [Related]
5. (99m)Tc-DTPA scintigraphy assesses the absence of glomerular filtration rate impairment of Aliskiren in high-risk hypertensive subjects. A 12-month follow-up study.
Mazza A; Montemurro D; Maffione AM; Vescovo G; Rampin L; Zuin M; Schiavon L; Camerotto A; Marzola MC; Fiorini F; Rubello D
Minerva Cardioangiol; 2014 Aug; 62(4):311-20. PubMed ID: 25012100
[TBL] [Abstract][Full Text] [Related]
6. Use of aliskiren in Latin America in a real-world setting: aliskiren in Latin America Study (ALAS).
Volman S; Benitez FN; Cedenio H; Giorgi M; Jaramillo N; Molina N; Zilberman J
Ther Adv Cardiovasc Dis; 2013 Aug; 7(4):189-96. PubMed ID: 23723254
[TBL] [Abstract][Full Text] [Related]
7. Aliskiren as add-on therapy in the treatment of hypertensive diabetic patients inadequately controlled with valsartan/HCT combination: a placebo-controlled study.
Drummond W; Sirenko YM; Ramos E; Baek I; Keefe DL
Am J Cardiovasc Drugs; 2011 Oct; 11(5):327-33. PubMed ID: 21846154
[TBL] [Abstract][Full Text] [Related]
8. [Does the rennin inhibitor aliskiren offer promising novel opportunities in the treatment of cardiovascular diseases?].
Horký K
Vnitr Lek; 2007 Apr; 53(4):364-70. PubMed ID: 17578167
[TBL] [Abstract][Full Text] [Related]
9. Comparative effects of aliskiren-based and ramipril-based therapy on the renin system during long-term (6 months) treatment and withdrawal in patients with hypertension.
Andersen K; Weinberger MH; Constance CM; Ali MA; Jin J; Prescott MF; Keefe DL
J Renin Angiotensin Aldosterone Syst; 2009 Sep; 10(3):157-67. PubMed ID: 19617271
[TBL] [Abstract][Full Text] [Related]
10. Comparative efficacy of aliskiren monotherapy and ramipril monotherapy in patients with stage 2 systolic hypertension: subgroup analysis of a double-blind, active comparator trial.
Andersen K; Weinberger MH; Egan B; Constance CM; Wright M; Lukashevich V; Keefe DL
Cardiovasc Ther; 2010 Dec; 28(6):344-9. PubMed ID: 20406241
[TBL] [Abstract][Full Text] [Related]
11. Efficacy analysis of the renoprotective effects of aliskiren in hypertensive patients with chronic kidney disease.
Abe M; Suzuki H; Okada K; Maruyama N; Inoshita A; Baba S; Takashima H; Soma M
Heart Vessels; 2013 Jul; 28(4):442-52. PubMed ID: 22618635
[TBL] [Abstract][Full Text] [Related]
12. Renin inhibition with aliskiren provides additive antihypertensive efficacy when used in combination with hydrochlorothiazide.
Villamil A; Chrysant SG; Calhoun D; Schober B; Hsu H; Matrisciano-Dimichino L; Zhang J
J Hypertens; 2007 Jan; 25(1):217-26. PubMed ID: 17143194
[TBL] [Abstract][Full Text] [Related]
13. Renin inhibition in hypertension.
Gradman AH; Kad R
J Am Coll Cardiol; 2008 Feb; 51(5):519-28. PubMed ID: 18237679
[TBL] [Abstract][Full Text] [Related]
14. An observational, prospective, open-label, multicentre evaluation of aliskiren in treated, uncontrolled patients: a real-life, long-term, follow-up, clinical practice in Italy.
Tocci G; Aimo G; Caputo D; De Matteis C; Di Napoli T; Granatelli A; Lentini P; Magagna A; Matarrese AA; Perona D; Villa G; Volpe M;
High Blood Press Cardiovasc Prev; 2012 Jun; 19(2):73-83. PubMed ID: 22867093
[TBL] [Abstract][Full Text] [Related]
15. Long-term antihypertensive effects of aliskiren, a direct renin inhibitor, in chronic hemodialysis patients.
Ishimitsu T; Ohta S; Ohno E; Takahashi T; Numabe A; Okamura A; Ohba S; Hashimoto A; Matsuoka H
Ther Apher Dial; 2013 Oct; 17(5):524-31. PubMed ID: 24107281
[TBL] [Abstract][Full Text] [Related]
16. Aliskiren for the treatment of essential hypertension under real-life practice conditions: design and baseline data of the prospective 3A registry.
Zeymer U; Dechend R; Deeg E; Kaiser E; Senges J; Pittrow D; Schmieder R;
Int J Clin Pract; 2012 Mar; 66(3):251-61. PubMed ID: 22321062
[TBL] [Abstract][Full Text] [Related]
17. Long-term safety and tolerability of the oral direct renin inhibitor aliskiren with optional add-on hydrochlorothiazide in patients with hypertension: a randomized, open-label, parallel-group, multicentre, dose-escalation study with an extension phase.
Sica D; Gradman AH; Lederballe O; Kolloch RE; Zhang J; Keefe DL
Clin Drug Investig; 2011 Dec; 31(12):825-37. PubMed ID: 22035463
[TBL] [Abstract][Full Text] [Related]
18. Effect of the direct Renin inhibitor aliskiren, the Angiotensin receptor blocker losartan, or both on left ventricular mass in patients with hypertension and left ventricular hypertrophy.
Solomon SD; Appelbaum E; Manning WJ; Verma A; Berglund T; Lukashevich V; Cherif Papst C; Smith BA; Dahlöf B;
Circulation; 2009 Feb; 119(4):530-7. PubMed ID: 19153265
[TBL] [Abstract][Full Text] [Related]
19. Aldosterone breakthrough during aliskiren, valsartan, and combination (aliskiren + valsartan) therapy.
Bomback AS; Rekhtman Y; Klemmer PJ; Canetta PA; Radhakrishnan J; Appel GB
J Am Soc Hypertens; 2012; 6(5):338-45. PubMed ID: 22995802
[TBL] [Abstract][Full Text] [Related]
20. Aliskiren and valsartan in stage 2 hypertension: subgroup analysis of a randomized, double-blind study.
Yarows SA; Oparil S; Patel S; Fang H; Zhang J
Adv Ther; 2008 Dec; 25(12):1288-302. PubMed ID: 19066757
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
